Cargando…

The Ferroptosis-Related Noncoding RNA Signature as a Novel Prognostic Biomarker in the Tumor Microenvironment, Immunotherapy, and Drug Screening of Gastric Adenocarcinoma

BACKGROUND: Ferroptosis is a new type of cell death different from apoptosis, necrosis, autophagy, and pyroptosis. This study aimed to explore the relationship between ferroptosis-related noncoding RNA (ncRNA) and gastric adenocarcinoma with regard to immunity and prognosis. METHODS: Ferroptosis-rel...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xinming, Zhu, Zheng, Li, Xiaoling, Yao, Xinyue, Luo, Lianxiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8591298/
https://www.ncbi.nlm.nih.gov/pubmed/34790582
http://dx.doi.org/10.3389/fonc.2021.778557
_version_ 1784599197699276800
author Chen, Xinming
Zhu, Zheng
Li, Xiaoling
Yao, Xinyue
Luo, Lianxiang
author_facet Chen, Xinming
Zhu, Zheng
Li, Xiaoling
Yao, Xinyue
Luo, Lianxiang
author_sort Chen, Xinming
collection PubMed
description BACKGROUND: Ferroptosis is a new type of cell death different from apoptosis, necrosis, autophagy, and pyroptosis. This study aimed to explore the relationship between ferroptosis-related noncoding RNA (ncRNA) and gastric adenocarcinoma with regard to immunity and prognosis. METHODS: Ferroptosis-related ncRNA expression profiles and clinical pathology and overall survival information were collected from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus database. The ferroptosis-related ncRNA signature was identified by Cox regression analysis and the least absolute shrinkage and selection operator analysis. The survival analysis, receiver operating characteristic (ROC) analysis, and decision curve analysis were adopted to evaluate the prognostic prediction performance of the signature. The correlation between risk and multiple clinical characteristics was analyzed using the chi-square test. The Gene Ontology, Kyoto Encyclopedia of Genes and Genomes, and gene set enrichment analysis were used for mining functions and pathways. The CIBERSORT, ssGSEA, and ESTIMATE algorithms were used to assess immune infiltration and the tumor microenvironment. The response of immunotherapy was predicted using the Submap algorithm, and the Connectivity Map and the ridge regression model were used to screen and evaluate drugs. RESULTS: A carcinogenic risk signature was constructed using five ferroptosis-related ncRNAs. It showed an extraordinary ability to predict the prognoses of patients with gastric adenocarcinoma [area under the ROC curve (AUC) after 6 years = 0.689; GSE84426, AUC after 6 years = 0.747]. The lower ferroptosis potential level and lower tumor mutation burden were related to the poor prognoses of patients. The high-risk group had more immune cell recruitment, and the overall effect of the anti-immune checkpoint immunotherapy was not as good as that of the low-risk group. The high- and low-risk groups were enriched in tumor- and immune-related pathways, respectively. The screened antitumor drugs, such as genistein, guanabenz, and betulinic acid, improved the survival of the patients. CONCLUSIONS: The ferroptosis-related ncRNA signature is a potential carcinogenic prognostic biomarker of gastric adenocarcinoma.
format Online
Article
Text
id pubmed-8591298
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-85912982021-11-16 The Ferroptosis-Related Noncoding RNA Signature as a Novel Prognostic Biomarker in the Tumor Microenvironment, Immunotherapy, and Drug Screening of Gastric Adenocarcinoma Chen, Xinming Zhu, Zheng Li, Xiaoling Yao, Xinyue Luo, Lianxiang Front Oncol Oncology BACKGROUND: Ferroptosis is a new type of cell death different from apoptosis, necrosis, autophagy, and pyroptosis. This study aimed to explore the relationship between ferroptosis-related noncoding RNA (ncRNA) and gastric adenocarcinoma with regard to immunity and prognosis. METHODS: Ferroptosis-related ncRNA expression profiles and clinical pathology and overall survival information were collected from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus database. The ferroptosis-related ncRNA signature was identified by Cox regression analysis and the least absolute shrinkage and selection operator analysis. The survival analysis, receiver operating characteristic (ROC) analysis, and decision curve analysis were adopted to evaluate the prognostic prediction performance of the signature. The correlation between risk and multiple clinical characteristics was analyzed using the chi-square test. The Gene Ontology, Kyoto Encyclopedia of Genes and Genomes, and gene set enrichment analysis were used for mining functions and pathways. The CIBERSORT, ssGSEA, and ESTIMATE algorithms were used to assess immune infiltration and the tumor microenvironment. The response of immunotherapy was predicted using the Submap algorithm, and the Connectivity Map and the ridge regression model were used to screen and evaluate drugs. RESULTS: A carcinogenic risk signature was constructed using five ferroptosis-related ncRNAs. It showed an extraordinary ability to predict the prognoses of patients with gastric adenocarcinoma [area under the ROC curve (AUC) after 6 years = 0.689; GSE84426, AUC after 6 years = 0.747]. The lower ferroptosis potential level and lower tumor mutation burden were related to the poor prognoses of patients. The high-risk group had more immune cell recruitment, and the overall effect of the anti-immune checkpoint immunotherapy was not as good as that of the low-risk group. The high- and low-risk groups were enriched in tumor- and immune-related pathways, respectively. The screened antitumor drugs, such as genistein, guanabenz, and betulinic acid, improved the survival of the patients. CONCLUSIONS: The ferroptosis-related ncRNA signature is a potential carcinogenic prognostic biomarker of gastric adenocarcinoma. Frontiers Media S.A. 2021-11-01 /pmc/articles/PMC8591298/ /pubmed/34790582 http://dx.doi.org/10.3389/fonc.2021.778557 Text en Copyright © 2021 Chen, Zhu, Li, Yao and Luo https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Chen, Xinming
Zhu, Zheng
Li, Xiaoling
Yao, Xinyue
Luo, Lianxiang
The Ferroptosis-Related Noncoding RNA Signature as a Novel Prognostic Biomarker in the Tumor Microenvironment, Immunotherapy, and Drug Screening of Gastric Adenocarcinoma
title The Ferroptosis-Related Noncoding RNA Signature as a Novel Prognostic Biomarker in the Tumor Microenvironment, Immunotherapy, and Drug Screening of Gastric Adenocarcinoma
title_full The Ferroptosis-Related Noncoding RNA Signature as a Novel Prognostic Biomarker in the Tumor Microenvironment, Immunotherapy, and Drug Screening of Gastric Adenocarcinoma
title_fullStr The Ferroptosis-Related Noncoding RNA Signature as a Novel Prognostic Biomarker in the Tumor Microenvironment, Immunotherapy, and Drug Screening of Gastric Adenocarcinoma
title_full_unstemmed The Ferroptosis-Related Noncoding RNA Signature as a Novel Prognostic Biomarker in the Tumor Microenvironment, Immunotherapy, and Drug Screening of Gastric Adenocarcinoma
title_short The Ferroptosis-Related Noncoding RNA Signature as a Novel Prognostic Biomarker in the Tumor Microenvironment, Immunotherapy, and Drug Screening of Gastric Adenocarcinoma
title_sort ferroptosis-related noncoding rna signature as a novel prognostic biomarker in the tumor microenvironment, immunotherapy, and drug screening of gastric adenocarcinoma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8591298/
https://www.ncbi.nlm.nih.gov/pubmed/34790582
http://dx.doi.org/10.3389/fonc.2021.778557
work_keys_str_mv AT chenxinming theferroptosisrelatednoncodingrnasignatureasanovelprognosticbiomarkerinthetumormicroenvironmentimmunotherapyanddrugscreeningofgastricadenocarcinoma
AT zhuzheng theferroptosisrelatednoncodingrnasignatureasanovelprognosticbiomarkerinthetumormicroenvironmentimmunotherapyanddrugscreeningofgastricadenocarcinoma
AT lixiaoling theferroptosisrelatednoncodingrnasignatureasanovelprognosticbiomarkerinthetumormicroenvironmentimmunotherapyanddrugscreeningofgastricadenocarcinoma
AT yaoxinyue theferroptosisrelatednoncodingrnasignatureasanovelprognosticbiomarkerinthetumormicroenvironmentimmunotherapyanddrugscreeningofgastricadenocarcinoma
AT luolianxiang theferroptosisrelatednoncodingrnasignatureasanovelprognosticbiomarkerinthetumormicroenvironmentimmunotherapyanddrugscreeningofgastricadenocarcinoma
AT chenxinming ferroptosisrelatednoncodingrnasignatureasanovelprognosticbiomarkerinthetumormicroenvironmentimmunotherapyanddrugscreeningofgastricadenocarcinoma
AT zhuzheng ferroptosisrelatednoncodingrnasignatureasanovelprognosticbiomarkerinthetumormicroenvironmentimmunotherapyanddrugscreeningofgastricadenocarcinoma
AT lixiaoling ferroptosisrelatednoncodingrnasignatureasanovelprognosticbiomarkerinthetumormicroenvironmentimmunotherapyanddrugscreeningofgastricadenocarcinoma
AT yaoxinyue ferroptosisrelatednoncodingrnasignatureasanovelprognosticbiomarkerinthetumormicroenvironmentimmunotherapyanddrugscreeningofgastricadenocarcinoma
AT luolianxiang ferroptosisrelatednoncodingrnasignatureasanovelprognosticbiomarkerinthetumormicroenvironmentimmunotherapyanddrugscreeningofgastricadenocarcinoma